Silverfin false false 31/12/2025 01/01/2025 31/12/2025 Dr J Faulkner 11/03/2024 M Schreiber 05/04/2022 Dr V Tripathi 25/03/2021 02 June 2026 no description of principal activity 13291464 2025-12-31 13291464 bus:Director1 2025-12-31 13291464 bus:Director2 2025-12-31 13291464 bus:Director3 2025-12-31 13291464 core:CurrentFinancialInstruments 2025-12-31 13291464 core:CurrentFinancialInstruments 2024-12-31 13291464 2024-12-31 13291464 core:ShareCapital 2025-12-31 13291464 core:ShareCapital 2024-12-31 13291464 core:SharePremium 2025-12-31 13291464 core:SharePremium 2024-12-31 13291464 core:OtherCapitalReserve 2025-12-31 13291464 core:OtherCapitalReserve 2024-12-31 13291464 core:RetainedEarningsAccumulatedLosses 2025-12-31 13291464 core:RetainedEarningsAccumulatedLosses 2024-12-31 13291464 bus:OrdinaryShareClass1 2025-12-31 13291464 2025-01-01 2025-12-31 13291464 bus:FilletedAccounts 2025-01-01 2025-12-31 13291464 bus:SmallEntities 2025-01-01 2025-12-31 13291464 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 13291464 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 13291464 bus:Director1 2025-01-01 2025-12-31 13291464 bus:Director2 2025-01-01 2025-12-31 13291464 bus:Director3 2025-01-01 2025-12-31 13291464 2024-01-01 2024-12-31 13291464 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 13291464 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 13291464 (England and Wales)

VITARKA THERAPEUTICS LTD

Unaudited Financial Statements
For the financial year ended 31 December 2025
Pages for filing with the registrar

VITARKA THERAPEUTICS LTD

Unaudited Financial Statements

For the financial year ended 31 December 2025

Contents

VITARKA THERAPEUTICS LTD

COMPANY INFORMATION

For the financial year ended 31 December 2025
VITARKA THERAPEUTICS LTD

COMPANY INFORMATION (continued)

For the financial year ended 31 December 2025
Directors Dr J Faulkner
M Schreiber
Dr V Tripathi
Registered office Innovation House Innovation Way
Discovery Park
Sandwich
CT13 9FF
United Kingdom
Company number 13291464 (England and Wales)
Accountant Kreston Reeves LLP
Suite 2
Orchard House
Orchard Street
Canterbury
Kent
CT2 8AR
VITARKA THERAPEUTICS LTD

BALANCE SHEET

As at 31 December 2025
VITARKA THERAPEUTICS LTD

BALANCE SHEET (continued)

As at 31 December 2025
Note 2025 2024
£ £
Restated
Current assets
Debtors 3 1,752 33,033
Cash at bank and in hand 4 480,717 403,678
482,469 436,711
Creditors: amounts falling due within one year 5 ( 20,768) ( 17,735)
Net current assets 461,701 418,976
Total assets less current liabilities 461,701 418,976
Net assets 461,701 418,976
Capital and reserves
Called-up share capital 6 141 141
Share premium account 872,553 872,553
Other reserves 8 680,000 340,000
Profit and loss account ( 1,090,993 ) ( 793,718 )
Total shareholders' funds 461,701 418,976

For the financial year ending 31 December 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Vitarka Therapeutics Ltd (registered number: 13291464) were approved and authorised for issue by the Board of Directors on 02 June 2026. They were signed on its behalf by:

Dr V Tripathi
Director
VITARKA THERAPEUTICS LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
VITARKA THERAPEUTICS LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Vitarka Therapeutics Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Innovation House Innovation Way, Discovery Park, Sandwich, CT13 9FF, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Profit and Loss Account in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Financial assets are derecognised when and only when the contractual rights to the cash flows from the financial asset expire or are settled, or the Company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or the Company, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.

Government grants

Government grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised. Grants relating to assets are recognised over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income.

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

2. Employees

2025 2024
Number Number
Monthly average number of persons employed by the Company during the year, including directors 3 2

3. Debtors

2025 2024
£ £
Corporation tax 0 23,742
Other debtors 1,752 9,291
1,752 33,033

4. Cash and cash equivalents

2025 2024
£ £
Cash at bank and in hand 480,717 403,678

5. Creditors: amounts falling due within one year

2025 2024
£ £
Accruals 18,780 10,190
Other taxation and social security 0 5,220
Other creditors 1,988 2,325
20,768 17,735

6. Called-up share capital

2025 2024
£ £
Allotted, called-up and fully-paid
1,405,878 Ordinary shares of £ 0.0001 each 141 141

7. Financial commitments

Pensions

The Company operates a defined contribution pension scheme for the directors and employees. The assets of the scheme are held separately from those of the Company in an independently administered fund.

2025 2024
£ £
Unpaid contributions due to the fund (inc. in other creditors) 1,988 2,325

8. Reserves

Share Premium

The share premium reserve records the amount above nominal value received for the shares issued by the company. Share premium may only be utilised to write-off any expenses incurred or commissions paid on the issue of those shares, or to pay up new shares to be allotted to members as fully paid bonus shares.

Profit and loss account

The profit and loss reserve comprises all current and prior period retained profits and losses after deducting any distributions made to the Company's shareholders.

Other reserves

Other reserves relate to funds received under a Simple Agreement for Future Equity (“SAFE”). The SAFE provides the investor with the right to receive equity shares on a future qualifying event. The amount recognised represents the proceeds received which have been classified as equity and have not yet converted into share capital.

9. Ultimate controlling party

The ultimate controlling party of the company is V Tripathi by virtue of her majority shareholding.